Grant: Doctoral: Vanier Canada Graduate Scholarships
McMaster University
$150,000.00
Developing and enhancing novel cancer immunotherapies by harnessing the anti-cancer abilities of patients' own Natural Killer immune cells
EF 2018-19
Résumé
Ovarian and lung cancer are among the most deadly cancers; the majority of patients with these diseases do not survive 5 years. For such poor prognosis cancers, there is a critical need for new effective treatments. The body's immune system is its primary protection mechanism against cancer: immune cells constantly survey the body and eliminate cancerous cells. However, cancer develops when malignant cells overwhelm this system. Therefore, reinforcing the body's natural immune defenses against cancer in the form of immunotherapy is emerging as a promising treatment modality for cancers that are resistant to current therapies. Natural Killer (NK) cells are immune cells that play a critical role in the body's defense against cancer due to their capacity to kill cancer cells without harming healthy cells. Given this ability, they have attracted attention as a promising cancer immunotherapy and have proven effective in treating blood cancers. Despite the therapeutic potential, immune therapies including NK cells have had limited success against solid tumours, such as ovarian and lung cancer, due to the hostile environment produced by tumours which impairs immune cell function. This impairment also limits efficacy of current therapies, such as antibody therapies which function largely through NK cells. Thus, understanding how the tumour environment alters NK cells is paramount to developing strategies to block inhibition and extend their therapeutic ability to solid tumours. The current project will uncover key changes in NK cells that impair their function after exposure to the tumour environment. Once identified, we will assess if blocking these changes can overcome NK cell inhibition and improve their therapeutic ability to reduce tumour burden. This project will uncover feasible targets to enhance NK cell function against ovarian and lung cancer in order to provide new effective therapies and improve outcomes of current therapies for cancers with poor prognosis.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
396249
Name
Poznanski Sophie M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Developing and enhancing novel cancer immunotherapies by harnessing the anti-cancer abilities of patients' own Natural Killer immune cells
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Adoptive Cell Therapy; Cancer Immunotherapy; Cell Metabolism; Immunology; Lung Cancer; Natural Killer Cells; Ovarian Cancer; Tumour Microenvironment
Abstract
Ovarian and lung cancer are among the most deadly cancers; the majority of patients with these diseases do not survive 5 years. For such poor prognosis cancers, there is a critical need for new effective treatments. The body's immune system is its primary protection mechanism against cancer: immune cells constantly survey the body and eliminate cancerous cells. However, cancer develops when malignant cells overwhelm this system. Therefore, reinforcing the body's natural immune defenses against cancer in the form of immunotherapy is emerging as a promising treatment modality for cancers that are resistant to current therapies. Natural Killer (NK) cells are immune cells that play a critical role in the body's defense against cancer due to their capacity to kill cancer cells without harming healthy cells. Given this ability, they have attracted attention as a promising cancer immunotherapy and have proven effective in treating blood cancers. Despite the therapeutic potential, immune therapies including NK cells have had limited success against solid tumours, such as ovarian and lung cancer, due to the hostile environment produced by tumours which impairs immune cell function. This impairment also limits efficacy of current therapies, such as antibody therapies which function largely through NK cells. Thus, understanding how the tumour environment alters NK cells is paramount to developing strategies to block inhibition and extend their therapeutic ability to solid tumours. The current project will uncover key changes in NK cells that impair their function after exposure to the tumour environment. Once identified, we will assess if blocking these changes can overcome NK cell inhibition and improve their therapeutic ability to reduce tumour burden. This project will uncover feasible targets to enhance NK cell function against ovarian and lung cancer in order to provide new effective therapies and improve outcomes of current therapies for cancers with poor prognosis.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Poznanski, Sophie M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~